Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy

AIDS

Volumn 15, Issue 12, 2001, Pages 1503-1508

  Moyle, Graeme J ^a   Lloyd, Michelle ^a   Reynolds, Brian ^a   Baldwin, Christine ^a   Mandalia, Sundiya ^a   Gazzard, Brian G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Diet; HIV protease inhibitors; Hypercholesterolaemia; Pravastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LOW DENSITY LIPOPROTEIN; NELFINAVIR; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL;

ARTICLE; BASAL METABOLIC RATE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIET SUPPLEMENTATION; DRUG CHOICE; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MALE; PRIORITY JOURNAL; PROTEINASE INHIBITION; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYPERCHOLESTEROLEMIA; MALE; PRAVASTATIN; VIRAL LOAD;

EID: 0035902911     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200108170-00007     Document Type: Article

References (24)

1. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
2. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation
3. Cholesterol metabolism in man
4. Oral statins and increased bone-mineral density in postmenopausal women
5. Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells
6. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
8. Effect of plasma cholesterol reduction by pravastatin on the functional properties of forearm arteries in hyperchoesterolemic patients
9. Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hyperchoesterolemic patients
10. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
11. Atorvastatin for protease inhibitor-related hyperlipidaemia
12. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitors-associated hyperlipidemias: A pilot study
13. Comparative pharmacokinetics of lovastatin, simvistatin and pravastatin in humans
14. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors
15. HMG-CoA reductase inhibitors and myotoxicity
16. Dietitian intervention improves lipid values and saves medication costs in men with combined hyperlipidemia and a history of niacin noncompliance
17. Atorvastatin and gemfibrozil for protease-inhibitor-associated lipid abnormalities
18. Biological variation in serum lipid concentrations
19. Comparison of dietary assessment methods in nutritional epidemiology; weighed records versus 24 hour recalls, food frequency questionnaires and estimated diet records
20. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductaase inhibitors
21. Switching from a protease inhibitor (PI)-based to a Pl-sparing regimen for the management of metabolic or clinical fat redistribution